ARWR

Company Overview — What Does ARROWHEAD PHARMACEUTICALS, INC. Do?

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Christopher R. Anzalone and employs approximately 400 people, headquartered in Pasadena, California. With a market capitalization of $8.8B, ARWR is one of the notable companies in the Healthcare sector.

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Stock Rating — Reduce (April 2026)

As of April 2026, ARROWHEAD PHARMACEUTICALS, INC. receives a Reduce rating with a composite score of 36.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ARWR ranks #2,846 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ARROWHEAD PHARMACEUTICALS, INC. ranks #396 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ARWR Stock Price and 52-Week Range

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) currently trades at $65.14. The stock lost $1.09 (1.6%) in the most recent trading session. The 52-week high for ARWR is $76.76, which means the stock is currently trading -15.1% from its annual peak. The 52-week low is $9.57, putting the stock 580.7% above its annual trough. Recent trading volume was 1.7M shares, reflecting moderate market activity.

Is ARWR Overvalued or Undervalued? — Valuation Analysis

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) carries a value factor score of 39/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 197.06x, compared to the Healthcare sector average of 23.63x — a premium of 734%. The price-to-book ratio stands at 15.23x, versus the sector average of 2.75x. The price-to-sales ratio is 10.27x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ARWR trades at 87.68x EV/EBITDA, versus 6.34x for the sector.

At current multiples, ARROWHEAD PHARMACEUTICALS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ARROWHEAD PHARMACEUTICALS, INC. Profitability — ROE, Margins, and Quality Score

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 7.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 2.7% versus the sector average of -33.1%.

The operating margin is -170.2% (sector: -66.1%). Net profit margin stands at -188.3%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ARWR Debt, Balance Sheet, and Financial Health

ARROWHEAD PHARMACEUTICALS, INC. has a debt-to-equity ratio of 185.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 3.38x, indicating strong short-term liquidity.

ARWR has a beta of 1.66, meaning it is more volatile than the broader market — a $10,000 investment in ARWR would be expected to move 66.2% more than the S&P 500 on any given day. The stability factor score for ARROWHEAD PHARMACEUTICALS, INC. is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ARROWHEAD PHARMACEUTICALS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ARROWHEAD PHARMACEUTICALS, INC. reported revenue of $835M and earnings per share (EPS) of $0.22. Net income for the quarter was $43M. Operating income came in at $80M.

In Q1 2026, ARROWHEAD PHARMACEUTICALS, INC. reported revenue of $264M and earnings per share (EPS) of $0.22. Net income for the quarter was $28M. Operating income came in at $41M.

In FY 2025, ARROWHEAD PHARMACEUTICALS, INC. reported revenue of $829M and earnings per share (EPS) of $-0.01. Net income for the quarter was $30M. Revenue grew 23258.2% year-over-year compared to FY 2024. Operating income came in at $98M.

In Q3 2025, ARROWHEAD PHARMACEUTICALS, INC. reported revenue of $28M and earnings per share (EPS) of $-1.26. Net income for the quarter was $-179M. Operating income came in at $-166M.

Over the past 8 quarters, ARROWHEAD PHARMACEUTICALS, INC. has demonstrated a growth trajectory, with revenue expanding from $0 to $835M. Investors analyzing ARWR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ARWR Dividend Yield and Income Analysis

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ARWR Momentum and Technical Analysis Profile

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has a momentum factor score of 69/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 9/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ARWR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ARROWHEAD PHARMACEUTICALS, INC. (ARWR) ranks #396 out of 838 stocks based on the Blank Capital composite score. This places ARWR in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ARWR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ARWR vs S&P 500 (SPY) comparison to assess how ARROWHEAD PHARMACEUTICALS, INC. stacks up against the broader market across all factor dimensions.

ARWR Next Earnings Date

No upcoming earnings date has been announced for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ARWR? — Investment Thesis Summary

The quantitative profile for ARROWHEAD PHARMACEUTICALS, INC. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 39/100 indicates premium valuation. Price momentum is positive at 69/100, suggesting the trend favors buyers. High volatility (stability score 34/100) increases portfolio risk.

In summary, ARROWHEAD PHARMACEUTICALS, INC. (ARWR) earns a Reduce rating with a composite score of 36.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ARWR stock.

Related Resources for ARWR Investors

Explore more research and tools: ARWR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ARWR head-to-head with peers: ARWR vs AZN, ARWR vs SLGL, ARWR vs VMD.